Analysis of early colorectal cancer screening results based on multi-target fecal FIT-DNA combined detection technology

doi:10.3877/cma.j.issn.2095-3224.2019.06.013

Abstract

Abstract:

Objective

To explore the use of innovative non-invasive screening methods for colorectal cancer to improve the efficiency of colorectal cancer screening, and lay the foundation for early screening projects of colorectal cancer in China in future.

Methods

In the physical examination population of Harbin Medical University Cancer Hospital from 2016 to 2017, early screening of colorectal cancer based on multi-target fecal FIT-DNA combined detection technology was carried out, and the screening process and results are analyzed and summarized.

Results

A total of 594 subjects were performed with multi-target fecal FIT-DNA combined detection technique, of which 61 subjects were positive, with an overall positive rate of 10.27% (61/594). Among them, thirty-two subjects underwent colonoscopy, twenty-one subjects had abnormal colonoscopy results, ten subjects had no abnormalities in colonoscopy, and 1 subject had unknown colonoscopy results. The rate of colonoscopy abnormalities in males and females was 68.75% (18/29) and 100% (3/3). In addition, the sensitivity was 88.9% (24/27) and 42.8% (12/28) for confirmed colorectal cancer and adenoma, respectively.

Conclusion

Screening for colorectal cancer with multi-target fecal FIT-DNA combined detection technique in the physical examination population is economical and effective. In particular, non-invasive and convenient screening techniques can be used to improve colonoscopy compliance and detection rate.

Key words: Colorectal neoplasms, Heilongjiang Province, Physical examination population, Screening, Multi-target fecal FIT-DNA combined detection technology

Zhigang Ma, Xiaolin Zhu, Lihong Ma, Peng Han, Yiyou Chen, Liguo Wang, Qiang Li, Jingze Zhang, Yanqiao Zhang. Analysis of early colorectal cancer screening results based on multi-target fecal FIT-DNA combined detection technology[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2019, 08(06): 616-621.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2019.06.013

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2019/V08/I06/616

Figures/Tables 5

References 28

[1]	Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2018 [J]. International Journal of Cancer, 2018, 136(5): 359-386.
[2]	Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014[J].Chinese Journal of Cancer Research, 2018, 30(1): 1-12.
[3]	Redwood DG, Asay ED, Blake ID, et al. Stool DNA testing for screening detection of colorectal neoplasia in Alaska native people [J]. Gastroenterology, 2016, 91(1): 61-70.
[4]	Morikawa T, Kato J, Yamaji Y, et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population [J]. Gastroenterology, 2005, 129(2): 422-428.
[5]	郑树，张苏展，黄彦钦. 结直肠癌研究30年回顾和现状[J].实用肿瘤杂志, 2016, 30(1): 2-5.
[6]	李世荣. 现阶段我国大肠癌筛查策略的思考[J]. 胃肠病学和肝病学杂志, 2008, 17(4): 261-262.
[7]	陈坤，黄秋驰. 结直肠癌人群筛查研究进展[J]. 中国癌症防治杂志, 2017, 9(2): 94-99.
[8]	Imperiale TF,Ransohoff DF,Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal- cancer screening [J]. N Engl J Med, 2014, 371(2): 187-188.
[9]	马晨曦，关旭，王松，等. 粪便DNA检测技术在结直肠癌筛查中的应用现状及展望[J].中华胃肠外科杂志，2019，22(5)：491-494.
[10]	金水，王亚雷，衡苗, 等. 粪便潜血试验及粪便DNA检测对结直肠癌筛查的比较研究[J].安徽医科大学学报, 2019, 54(9): 1485-1488.
[11]	Lew J B, St D J, Xu X M, et al. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study [J]. Lancet Public Health, 2017, 2(7): e331.
[12]	Tanday S. Updated Canadian colorectal cancer screening guidelines [J]. Lancet Oncology, 2016, 17(4): e137-e137.
[13]	Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening [J]. CA Cancer J Clin, 2017, 67(2): 100-121.
[14]	代敏，石菊芳，李霓. 中国城市癌症早诊早治项目设计及预期目标[J]. 中华预防医学杂志, 2013, 47(2): 179-182.
[15]	李燕，刘华章，林国桢,等. 广州市2015年结直肠癌筛查结果分析[J]. 中国肿瘤, 2016, 25(6): 422-425.
[16]	郑莹，龚杨明，顾凯,等. 上海市社区居民结直肠癌筛查项目[J]. 上海预防医学, 2016, 28(10): 739-742.
[17]	曹泮悬，沈永洲，黄彦钦,等. 浙江省海宁市40~74岁目标人群结直肠癌早诊早治筛查结果分析[J]. 中国肿瘤, 2017, 26(3): 181-184.
[18]	李辉章，杜灵彬，孙校华, 等.浙江省城市居民癌症早诊早治项目筛查结果报告[J].浙江预防医学, 2015, 27(12): 1189-1193.
[19]	韩英，武子涛，李世荣, 等. 大肠癌伺机性筛查模式与中国国情[J]. 中华健康管理学杂志, 2012, 06(2): 73-74.
[20]	陈燕，李兆申，蔡全才, et al. 粪便脱落细胞检测应用于大肠癌筛查的研究进展[J]. 第二军医大学学报, 2007, 28(10): 1120-1122.
[21]	徐梅华，蔡克银. 大肠癌粪便DNA检测研究进展[J]. 癌症进展, 2012, 10(2): 145-148.
[22]	Houshmand M, Abbaszadegan M R, Kerachian M A. Assessment of Bone Morphogenetic Protein 3 Methylation in Iranian Patients with Colorectal Cancer [J]. Middle East Journal of Digestive Diseases, 2017, 9(3): 158.
[23]	Veerle M, Marjolein HF, Lentjes M, et al. N-Myc downstream regulated gene 4 (NDRG4): A candidate tumor suppressor gene and potential biomarker for colorectal cancer [J]. J Natl Cancer Inst, 2009, 101(13): 916-927.
[24]	Dong SM, T raverso G, Johnson C, et al. Detecting colorectal Cancer in stool with the use of multiple genetictargets [J]. J Natl Cancer Inst, 2001, 93: 858-865.
[25]	Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool feasibility of a multitarget assay panel. Gastroenterology, 2000, 119: 1219-1227.
[26]	Deenadayalu VP, Rex DK.Fecal based DNA assays: a new, noninvasive approach to colorectal cancer screening. Cleve Clin JMed, 2004, 71: 497-503.
[27]	中国抗癌协会大肠癌专业委员会中国结直肠肿瘤早诊筛查策略制订专家组. 中国结直肠肿瘤早诊筛查策略专家共识[J]. 中华胃肠外科杂志, 2018, 21(10): 1081-1084.
[28]	北京健康管理协会.防癌体检规范专家共识[M]. 北京: 人民卫生出版社, 2018.

?		完成例数	阳性例数（%）	阳性占比（%）
总计		594	61	10.27
性别		?	?	?
?	男	435	51	11.72
?	女	159	10	6.29
年龄（岁）		?	?	?
?	<40	124	11	8.87
?	40~49	135	11	8.15
?	50~59	194	17	8.76
?	60~69	90	8	8.89
?	70~74	18	5	27.78
?	>74	33	9	27.27

?		完成例数	阳性例数（%）	阳性占比（%）
总计		594	61	10.27
性别		?	?	?
?	男	435	51	11.72
?	女	159	10	6.29
年龄（岁）		?	?	?
?	<40	124	11	8.87
?	40~49	135	11	8.15
?	50~59	194	17	8.76
?	60~69	90	8	8.89
?	70~74	18	5	27.78
?	>74	33	9	27.27

?		FIT-DNA检测阳性例数	肠镜检查例数	肠镜依从率（%）
总计		61	32	52.46
性别		?	?	?
?	男	51	29	56.86
?	女	10	3	30.00
年龄（岁）		?	?	?
?	<40	11	7	63.64
?	40~49	11	8	72.73
?	50~59	17	10	58.82
?	60~69	8	3	37.50
?	70~74	5	2	40.00
?	>74	9	2	22.22

?		FIT-DNA检测阳性例数	肠镜检查例数	肠镜依从率（%）
总计		61	32	52.46
性别		?	?	?
?	男	51	29	56.86
?	女	10	3	30.00
年龄（岁）		?	?	?
?	<40	11	7	63.64
?	40~49	11	8	72.73
?	50~59	17	10	58.82
?	60~69	8	3	37.50
?	70~74	5	2	40.00
?	>74	9	2	22.22

?		肠镜异常类型
?		肠镜检查	肠炎/溃疡	息肉	腺瘤	肠镜异常总例数	肠镜异常比例（%）
总计		31	3	13	5	21	67.74
性别		?	?	?	?	?	?
?	男	28	2	12	4	18	64.29
?	女	3	1	1	1	3	100.00
年龄（岁）		?	?	?	?	?	?
?	<40	7	2	-	-	2	28.57
?	40~49	8	1	4	1	6	75.00
?	50~59	8	-	5	3	8	100.00
?	60~69	4	-	1	1	2	50.00
?	70~74	2	-	1	-	1	50.00
?	>74	2	-	2	-	2	100.00

Please choose a citation manager

Content to export